Clinical Hospital Centre Zemun

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes2 trials
• Chronic kidney disease1 trial
• Multiple myeloma1 trial
• Multiple sclerosis1 trial
• Ulcerative colitis1 trial

Phase

• Phase 34 trials
• Phase 11 trial
• Phase 21 trial

Status

• Completed3 trials
• Active, not recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Novo Nordisk A/S3 trials
• Eli Lilly and Company1 trial
• Hoffmann-La Roche1 trial
• Shanghai Henlius Biotech1 trial

Running trials

• Recruiting

  A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  NCT07477587· Phase 1· Shanghai Henlius Biotech· Source

  Contact: Yinping Zhong

• Active, not recruiting

  A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

  NCT06598943· Phase 2· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

  NCT04035005· Phase 3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma1 recruiting

Closed trials

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

  NCT06323174· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes

  NCT05813912· Phase 3· Novo Nordisk A/S· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source